JointHealth
français
Arthritis Medications Report Card
Where does your province rank?

Pharmaceutical policy discussions and announcements at both the national and provincial -territorial government levels are changing reimbursement access to treatment options for Canadians living with an inflammatory arthritis.

The JointHealth™ Arthritis Medications Report Card is designed to help Canadians evaluate where their province ranks in terms of providing reimbursement for medications approved for inflammatory arthritis such as rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis and juvenile idiopathic arthritis.

The JointHealth™ Arthritis Medications Report Card tracks advanced therapy disease modifying anti-rheumatic drugs (or DMARDs) used to treat the most common types of inflammatory arthritis:
  • Biologic response modifier (originator or “boDMARD”)
  • Biologic response modifier (biosimilar or “bsDMARD”)
  • Targeted synthetic molecule (tsDMARD)
If your province doesn’t measure up, ACE encourages you to write and speak to your elected provincial or federal representative about the lack of equitable reimbursement access and patient/physician choice in treating inflammatory forms of arthritis.

printer-friendly printer-friendly
Medications Chart : Updated June 2017
1st : Saskatchewan   (Last year: 4th)
generic name (Brand Name) rheumatoid arthritis axial spondyloarthritis juvenile idiopathic arthritis psoriatic arthritis systemic lupus erythematosus vasculitis osteoporosis
ankylosing spondylitis non-radiographic axial spondyloarthritis (not visible on X-ray)
abatacept (Orencia®) Listed—CBC N/A N/A Listed—CBC In Trials N/A N/A N/A
adalimumab (Humira®) Listed—CBC Listed—CBC N/A Listed—CBC Listed—CBC N/A N/A N/A
anakinra (Kineret®) Listed—CBC N/A N/A N/A N/A N/A N/A N/A
belimumab (Benlysta®) N/A N/A N/A N/A N/A Declined N/A N/A
canakinumab (Ilaris®) N/A N/A N/A Declined N/A N/A N/A N/A
certolizumab pegol (Cimzia®) Listed—CBC Listed—CBC N/A N/A Listed—CBC N/A N/A N/A
denosumab (Prolia®) N/A N/A N/A N/A N/A N/A N/A Listed—CBC
etanercept (Enbrel®, boDMARD) Listed—CBC Listed—CBC N/A Listed—CBC Listed—CBC N/A N/A N/A
etanercept (Brenzys®, bsDMARD) Under Review Under Review N/A N/A N/A N/A N/A N/A
etanercept (Erelzi®, bsDMARD) Under Review Under Review N/A N/A N/A N/A N/A N/A
golimumab (Simponi®) Listed—CBC Listed—CBC Under Review N/A Listed—CBC N/A N/A N/A
infliximab (Remicade®, boDMARD) Listed—CBC Listed—CBC N/A N/A Listed—CBC N/A N/A N/A
infliximab (Inflectra®, bsDMARD) Listed—CBC Listed—CBC N/A N/A Listed—CBC N/A N/A N/A
rituximab (Rituxan®) Listed—CBC N/A N/A N/A N/A N/A Listed—CBC N/A
sarilumab (Kevzara®) Under Review N/A N/A N/A N/A N/A N/A N/A
secukinumab (Cosentyx®) N/A Under Review N/A N/A Under Review N/A N/A N/A
tocilizumab (Actemra®) Listed—CBC N/A N/A Listed—CBC N/A N/A N/A N/A
ustekinumab (Stelara®) N/A N/A N/A N/A Listed—CBC N/A N/A N/A
apremilast (Otezla®) N/A N/A N/A N/A Under Review N/A N/A N/A
tofacitinib citrate (Xeljanz®) Listed—CBC N/A N/A N/A N/A N/A N/A N/A
1st : Ontario   (Last year: 3rd)
generic name (Brand Name) rheumatoid arthritis axial spondyloarthritis juvenile idiopathic arthritis psoriatic arthritis systemic lupus erythematosus vasculitis osteoporosis
ankylosing spondylitis non-radiographic axial spondyloarthritis (not visible on X-ray)
abatacept (Orencia®) Listed—CBC N/A N/A Listed—CBC In Trials N/A N/A N/A
adalimumab (Humira®) Listed—CBC Listed—CBC N/A Listed—CBC Listed—CBC N/A N/A N/A
anakinra (Kineret®) Listed—CBC N/A N/A Listed—CBC N/A N/A N/A N/A
belimumab (Benlysta®) N/A N/A N/A N/A N/A Declined N/A N/A
canakinumab (Ilaris®) N/A N/A N/A Under Review N/A N/A N/A N/A
certolizumab pegol (Cimzia®) Listed—CBC Listed—CBC N/A N/A Listed—CBC N/A N/A N/A
denosumab (Prolia®) N/A N/A N/A N/A N/A N/A N/A Listed—CBC
etanercept (Enbrel®, boDMARD) Listed—CBC Listed—CBC N/A Listed—CBC Listed—CBC N/A N/A N/A
etanercept (Brenzys®, bsDMARD) Under Review Under Review N/A N/A N/A N/A N/A N/A
etanercept (Erelzi®, bsDMARD) Under Review Under Review N/A N/A N/A N/A N/A N/A
golimumab (Simponi®) Listed—CBC Listed—CBC Under Review N/A Listed—CBC N/A N/A N/A
infliximab (Remicade®, boDMARD) Listed—ORC Listed—ORC N/A Listed—ORC Listed—ORC N/A N/A N/A
infliximab (Inflectra®, bsDMARD) Listed—CBC Listed—CBC N/A N/A Listed—CBC N/A N/A N/A
rituximab (Rituxan®) Listed—CBC N/A N/A N/A N/A N/A Listed—CBC N/A
sarilumab (Kevzara®) Under Review N/A N/A N/A N/A N/A N/A N/A
secukinumab (Cosentyx®) N/A Under Review N/A N/A Under Review N/A N/A N/A
tocilizumab (Actemra®) Listed—CBC N/A N/A Listed—CBC N/A N/A N/A N/A
ustekinumab (Stelara®) N/A N/A N/A N/A Declined N/A N/A N/A
apremilast (Otezla®) N/A N/A N/A N/A Under Review N/A N/A N/A
tofacitinib citrate (Xeljanz®) Listed—CBC N/A N/A N/A N/A N/A N/A N/A
3rd : Alberta   (Last year :7th)
generic name (Brand Name) rheumatoid arthritis axial spondyloarthritis juvenile idiopathic arthritis psoriatic arthritis systemic lupus erythematosus vasculitis osteoporosis
ankylosing spondylitis non-radiographic axial spondyloarthritis (not visible on X-ray)
abatacept (Orencia®) Listed—CBC N/A N/A Listed—ORC In Trials N/A N/A N/A
adalimumab (Humira®) Listed—CBC Listed—CBC N/A Listed—CBC Listed—CBC N/A N/A N/A
anakinra (Kineret®) Listed—CBC N/A N/A N/A N/A N/A N/A N/A
belimumab (Benlysta®) N/A N/A N/A N/A N/A Declined N/A N/A
canakinumab (Ilaris®) N/A N/A N/A Declined N/A N/A N/A N/A
certolizumab pegol (Cimzia®) Listed—CBC Listed—CBC N/A N/A Listed—CBC N/A N/A N/A
denosumab (Prolia®) N/A N/A N/A N/A N/A N/A N/A Listed—CBC
etanercept (Enbrel®, boDMARD) Listed—CBC Listed—CBC N/A Listed—CBC Listed—CBC N/A N/A N/A
etanercept (Brenzys®, bsDMARD) Under Review Under Review N/A N/A N/A N/A N/A N/A
etanercept (Erelzi®, bsDMARD) Under Review Under Review N/A N/A N/A N/A N/A N/A
golimumab (Simponi®) Listed—CBC Listed—CBC Under Review N/A Listed—CBC N/A N/A N/A
infliximab (Remicade®, boDMARD) Listed—ORC Listed—ORC N/A N/A Listed—ORC N/A N/A N/A
infliximab (Inflectra®, bsDMARD) Listed—CBC Listed—CBC N/A N/A Listed—CBC N/A N/A N/A
rituximab (Rituxan®) Listed—CBC N/A N/A N/A N/A N/A Listed—CBC N/A
sarilumab (Kevzara®) Under Review N/A N/A N/A N/A N/A N/A N/A
secukinumab (Cosentyx®) N/A Under Review N/A N/A Under Review N/A N/A N/A
tocilizumab (Actemra®) Listed—CBC N/A N/A Listed—CBC N/A N/A N/A N/A
ustekinumab (Stelara®) N/A N/A N/A N/A Under Review N/A N/A N/A
apremilast (Otezla®) N/A N/A N/A N/A Under Review N/A N/A N/A
tofacitinib citrate (Xeljanz®) Listed—CBC N/A N/A N/A N/A N/A N/A N/A
3rd : Québec   (Last year: 1st)
generic name (Brand Name) rheumatoid arthritis axial spondyloarthritis juvenile idiopathic arthritis psoriatic arthritis systemic lupus erythematosus vasculitis osteoporosis
ankylosing spondylitis non-radiographic axial spondyloarthritis (not visible on X-ray)
abatacept (Orencia®) Listed—CBC N/A N/A Listed—CBC In Trials N/A N/A N/A
adalimumab (Humira®) Listed—CBC Listed—CBC N/A Listed—CBC Listed—CBC N/A N/A N/A
anakinra (Kineret®) Declined N/A N/A N/A N/A N/A N/A N/A
belimumab (Benlysta®) N/A N/A N/A N/A N/A Declined N/A N/A
canakinumab (Ilaris®) N/A N/A N/A Under Review N/A N/A N/A N/A
certolizumab pegol (Cimzia®) Listed—CBC Listed—CBC N/A N/A Listed—CBC N/A N/A N/A
denosumab (Prolia®) N/A N/A N/A N/A N/A N/A N/A Listed—CBC
etanercept (Enbrel®, boDMARD) Listed—CBC Listed—CBC N/A Listed—CBC Listed—CBC N/A N/A N/A
etanercept (Brenzys®, bsDMARD) Under Review Under Review N/A N/A N/A N/A N/A N/A
etanercept (Erelzi®, bsDMARD) Under Review Under Review N/A N/A N/A N/A N/A N/A
golimumab (Simponi®) Listed—CBC Listed—CBC Under Review N/A Listed—CBC N/A N/A N/A
infliximab (Remicade®, boDMARD) Listed—ORC Listed—ORC N/A Listed—ORC Listed—ORC N/A N/A N/A
infliximab (Inflectra®, bsDMARD) Listed—CBC Listed—CBC N/A N/A Listed—CBC N/A N/A N/A
rituximab (Rituxan®) Listed—CBC N/A N/A N/A N/A N/A Under Review N/A
sarilumab (Kevzara®) Under Review N/A N/A N/A N/A N/A N/A N/A
secukinumab (Cosentyx®) N/A Declined N/A N/A Declined N/A N/A N/A
tocilizumab (Actemra®) Listed—CBC N/A N/A Listed—CBC N/A N/A N/A N/A
ustekinumab (Stelara®) N/A N/A N/A N/A Listed—CBC N/A N/A N/A
apremilast (Otezla®) N/A N/A N/A N/A Declined N/A N/A N/A
tofacitinib citrate (Xeljanz®) Listed—CBC N/A N/A N/A N/A N/A N/A N/A
5th : British Columbia   (Last year: 2nd)
generic name (Brand Name) rheumatoid arthritis axial spondyloarthritis juvenile idiopathic arthritis psoriatic arthritis systemic lupus erythematosus vasculitis osteoporosis
ankylosing spondylitis non-radiographic axial spondyloarthritis (not visible on X-ray)
abatacept (Orencia®) Listed—CBC N/A N/A Listed—CBC N/A N/A N/A N/A
adalimumab (Humira®) Listed—CBC Listed—CBC N/A Listed—CBC Listed—CBC N/A N/A N/A
anakinra (Kineret®) Declined N/A N/A N/A N/A N/A N/A N/A
belimumab (Benlysta®) N/A N/A N/A N/A N/A Declined N/A N/A
canakinumab (Ilaris®) N/A N/A N/A Declined N/A N/A N/A N/A
certolizumab pegol (Cimzia®) Listed—CBC Listed—CBC N/A N/A Listed—CBC N/A N/A N/A
denosumab (Prolia®) N/A N/A N/A N/A N/A N/A N/A Listed—CBC
etanercept (Enbrel®, boDMARD) Listed—CBC Listed—CBC N/A Listed—CBC Listed—CBC N/A N/A N/A
etanercept (Brenzys®, bsDMARD) Under Review Under Review N/A N/A N/A N/A N/A N/A
etanercept (Erelzi®, bsDMARD) Under Review Under Review N/A N/A N/A N/A N/A N/A
golimumab (Simponi®) Listed—CBC Listed—CBC Under Review N/A Listed—CBC N/A N/A N/A
infliximab (Remicade®, boDMARD) Listed—ORC Listed—ORC N/A N/A Listed—ORC N/A N/A N/A
infliximab (Inflectra®, bsDMARD) Listed—CBC Listed—CBC N/A N/A Listed—CBC N/A N/A N/A
rituximab (Rituxan®) Listed—CBC N/A N/A N/A N/A N/A Listed—CBC N/A
sarilumab (Kevzara®) Under Review N/A N/A N/A N/A N/A N/A N/A
secukinumab (Cosentyx®) N/A Under Review N/A N/A Under Review N/A N/A N/A
tocilizumab (Actemra®) Listed—CBC N/A N/A Listed—CBC N/A N/A N/A N/A
ustekinumab (Stelara®) N/A N/A N/A N/A Declined N/A N/A N/A
apremilast (Otezla®) N/A N/A N/A N/A Under Review N/A N/A N/A
tofacitinib citrate (Xeljanz®) Listed—CBC N/A N/A N/A N/A N/A N/A N/A
5th : Nova Scotia   (Last year: 4th)
generic name (Brand Name) rheumatoid arthritis axial spondyloarthritis juvenile idiopathic arthritis psoriatic arthritis systemic lupus erythematosus vasculitis osteoporosis
ankylosing spondylitis non-radiographic axial spondyloarthritis (not visible on X-ray)
abatacept (Orencia®) Listed—CBC N/A N/A Listed—CBC In Trials N/A N/A N/A
adalimumab (Humira®) Listed—CBC Listed—CBC N/A Listed—CBC Listed—CBC N/A N/A N/A
anakinra (Kineret®) Under Review N/A N/A N/A N/A N/A N/A N/A
belimumab (Benlysta®) N/A N/A N/A N/A N/A Under Review N/A N/A
canakinumab (Ilaris®) N/A N/A N/A Under Review N/A N/A N/A N/A
certolizumab pegol (Cimzia®) Listed—CBC Listed—CBC N/A N/A Listed—CBC N/A N/A N/A
denosumab (Prolia®) N/A N/A N/A N/A N/A N/A N/A Listed—CBC
etanercept (Enbrel®, boDMARD) Listed—CBC Listed—CBC N/A Listed—CBC Listed—CBC N/A N/A N/A
etanercept (Brenzys®, bsDMARD) Under Review Under Review N/A N/A N/A N/A N/A N/A
etanercept (Erelzi®, bsDMARD) Under Review Under Review N/A N/A N/A N/A N/A N/A
golimumab (Simponi®) Listed—CBC Listed—CBC Under Review N/A Listed—CBC N/A N/A N/A
infliximab (Remicade®, boDMARD) Listed—ORC Listed—ORC N/A N/A Listed—ORC N/A N/A N/A
infliximab (Inflectra®, bsDMARD) Listed—CBC Listed—CBC N/A N/A Listed—CBC N/A N/A N/A
rituximab (Rituxan®) Listed—CBC N/A N/A N/A N/A N/A Listed—CBC N/A
sarilumab (Kevzara®) Under Review N/A N/A N/A N/A N/A N/A N/A
secukinumab (Cosentyx®) N/A Under Review N/A N/A Under Review N/A N/A N/A
tocilizumab (Actemra®) Listed—CBC N/A N/A Listed—CBC N/A N/A N/A N/A
ustekinumab (Stelara®) N/A N/A N/A N/A Under Review N/A N/A N/A
apremilast (Otezla®) N/A N/A N/A N/A Under Review N/A N/A N/A
tofacitinib citrate (Xeljanz®) Listed—CBC N/A N/A N/A N/A N/A N/A N/A
5th : New Brunswick   (Last year: 8th)
generic name (Brand Name) rheumatoid arthritis axial spondyloarthritis juvenile idiopathic arthritis psoriatic arthritis systemic lupus erythematosus vasculitis osteoporosis
ankylosing spondylitis non-radiographic axial spondyloarthritis (not visible on X-ray)
abatacept (Orencia®) Listed—CBC N/A N/A Listed—CBC In Trials N/A N/A N/A
adalimumab (Humira®) Listed—CBC Listed—CBC N/A Listed—CBC Listed—CBC N/A N/A N/A
anakinra (Kineret®) Under Review N/A N/A N/A N/A N/A N/A N/A
belimumab (Benlysta®) N/A N/A N/A N/A N/A Declined N/A N/A
canakinumab (Ilaris®) N/A N/A N/A Declined N/A N/A N/A N/A
certolizumab pegol (Cimzia®) Listed—CBC Listed—CBC N/A N/A Listed—CBC N/A N/A N/A
denosumab (Prolia®) N/A N/A N/A N/A N/A N/A N/A Listed—CBC
etanercept (Enbrel®, boDMARD) Listed—CBC Listed—CBC N/A Listed—CBC Listed—CBC N/A N/A N/A
etanercept (Brenzys®, bsDMARD) Under Review Under Review N/A N/A N/A N/A N/A N/A
etanercept (Erelzi®, bsDMARD) Under Review Under Review N/A N/A N/A N/A N/A N/A
golimumab (Simponi®) Listed—CBC Listed—CBC Under Review N/A Listed—CBC N/A N/A N/A
infliximab (Remicade®, boDMARD) Listed—ORC Listed—ORC N/A N/A Listed—ORC N/A N/A N/A
infliximab (Inflectra®, bsDMARD) Listed—CBC Listed—CBC N/A N/A Listed—CBC N/A N/A N/A
rituximab (Rituxan®) Listed—CBC N/A N/A N/A N/A N/A Listed—CBC N/A
sarilumab (Kevzara®) Under Review N/A N/A N/A N/A N/A N/A N/A
secukinumab (Cosentyx®) N/A Under Review N/A N/A Under Review N/A N/A N/A
tocilizumab (Actemra®) Listed—CBC N/A N/A Listed—CBC N/A N/A N/A N/A
ustekinumab (Stelara®) N/A N/A N/A N/A Declined N/A N/A N/A
apremilast (Otezla®) N/A N/A N/A N/A Under Review N/A N/A N/A
tofacitinib citrate (Xeljanz®) Listed—CBC N/A N/A N/A N/A N/A N/A N/A
8th : Newfoundland and Labrador   (Last year: 10th)
generic name (Brand Name) rheumatoid arthritis axial spondyloarthritis juvenile idiopathic arthritis psoriatic arthritis systemic lupus erythematosus vasculitis osteoporosis
ankylosing spondylitis non-radiographic axial spondyloarthritis (not visible on X-ray)
abatacept (Orencia®) Listed—CBC N/A N/A Listed—CBC In Trials N/A N/A N/A
adalimumab (Humira®) Listed—CBC Listed—CBC N/A Listed—CBC Listed—CBC N/A N/A N/A
anakinra (Kineret®) Under Review N/A N/A N/A N/A N/A N/A N/A
belimumab (Benlysta®) N/A N/A N/A N/A N/A Under Review N/A N/A
canakinumab (Ilaris®) N/A N/A N/A Under Review N/A N/A N/A N/A
certolizumab pegol (Cimzia®) Listed—CBC Listed—CBC N/A N/A Listed—CBC N/A N/A N/A
denosumab (Prolia®) N/A N/A N/A N/A N/A N/A N/A Listed—CBC
etanercept (Enbrel®, boDMARD) Listed—CBC Listed—CBC N/A Listed—CBC Listed—CBC N/A N/A N/A
etanercept (Brenzys®, bsDMARD) Under Review Under Review N/A N/A N/A N/A N/A N/A
etanercept (Erelzi®, bsDMARD) Under Review Under Review N/A N/A N/A N/A N/A N/A
golimumab (Simponi®) Listed—CBC Listed—CBC Under Review N/A Listed—CBC N/A N/A N/A
infliximab (Remicade®, boDMARD) Listed—ORC Listed—ORC N/A N/A Declined N/A N/A N/A
infliximab (Inflectra®, bsDMARD) Listed—CBC Listed—CBC N/A N/A Listed—CBC N/A N/A N/A
rituximab (Rituxan®) Listed—CBC N/A N/A N/A N/A N/A Listed—CBC N/A
sarilumab (Kevzara®) Under Review N/A N/A N/A N/A N/A N/A N/A
secukinumab (Cosentyx®) N/A Under Review N/A N/A Under Review N/A N/A N/A
tocilizumab (Actemra®) Listed—CBC N/A N/A Listed—CBC N/A N/A N/A N/A
ustekinumab (Stelara®) N/A N/A N/A N/A Under Review N/A N/A N/A
apremilast (Otezla®) N/A N/A N/A N/A Under Review N/A N/A N/A
tofacitinib citrate (Xeljanz®) Listed—CBC N/A N/A N/A N/A N/A N/A N/A
9th : Manitoba   (Last year: 8th)
generic name (Brand Name) rheumatoid arthritis axial spondyloarthritis juvenile idiopathic arthritis psoriatic arthritis systemic lupus erythematosus vasculitis osteoporosis
ankylosing spondylitis non-radiographic axial spondyloarthritis (not visible on X-ray)
abatacept (Orencia®) Listed—CBC N/A N/A Under Review In Trials N/A N/A N/A
adalimumab (Humira®) Listed—CBC Listed—CBC N/A Listed—CBC Listed—CBC N/A N/A N/A
anakinra (Kineret®) Listed—CBC N/A N/A N/A N/A N/A N/A N/A
belimumab (Benlysta®) N/A N/A N/A N/A N/A Under Review N/A N/A
canakinumab (Ilaris®) N/A N/A N/A Under Review N/A N/A N/A N/A
certolizumab pegol (Cimzia®) Listed—CBC Listed—CBC N/A N/A Listed—CBC N/A N/A N/A
denosumab (Prolia®) N/A N/A N/A N/A N/A N/A N/A Listed—CBC
etanercept (Enbrel®, boDMARD) Listed—CBC Listed—CBC N/A Unknown Listed—CBC N/A N/A N/A
etanercept (Brenzys®, bsDMARD) Under Review Under Review N/A N/A N/A N/A N/A N/A
etanercept (Erelzi®, bsDMARD) Under Review Under Review N/A N/A N/A N/A N/A N/A
golimumab (Simponi®) Listed—CBC Listed—CBC Under Review N/A Listed—CBC N/A N/A N/A
infliximab (Remicade®, boDMARD) Listed—ORC Listed—ORC N/A N/A Listed—ORC N/A N/A N/A
infliximab (Inflectra®, bsDMARD) Listed—CBC Listed—CBC N/A N/A Listed—CBC N/A N/A N/A
rituximab (Rituxan®) Listed—CBC N/A N/A N/A N/A N/A Listed—CBC N/A
sarilumab (Kevzara®) Under Review N/A N/A N/A N/A N/A N/A N/A
secukinumab (Cosentyx®) N/A Under Review N/A N/A Under Review N/A N/A N/A
tocilizumab (Actemra®) Listed—CBC N/A N/A Listed—CBC N/A N/A N/A N/A
ustekinumab (Stelara®) N/A N/A N/A N/A Under Review N/A N/A N/A
apremilast (Otezla®) N/A N/A N/A N/A Under Review N/A N/A N/A
tofacitinib citrate (Xeljanz®) Listed—CBC N/A N/A N/A N/A N/A N/A N/A
9th : Prince Edward Island   (Last year: 6th)
generic name (Brand Name) rheumatoid arthritis axial spondyloarthritis juvenile idiopathic arthritis psoriatic arthritis systemic lupus erythematosus vasculitis osteoporosis
ankylosing spondylitis non-radiographic axial spondyloarthritis (not visible on X-ray)
abatacept (Orencia®) Listed—CBC N/A N/A Listed—CBC In Trials N/A N/A N/A
adalimumab (Humira®) Listed—CBC Listed—CBC N/A Listed—CBC Listed—CBC N/A N/A N/A
anakinra (Kineret®) Under Review N/A N/A N/A N/A N/A N/A N/A
belimumab (Benlysta®) N/A N/A N/A N/A N/A Under Review N/A N/A
canakinumab (Ilaris®) N/A N/A N/A Under Review N/A N/A N/A N/A
certolizumab pegol (Cimzia®) Listed—CBC Listed—CBC N/A N/A Listed—CBC N/A N/A N/A
denosumab (Prolia®) N/A N/A N/A N/A N/A N/A N/A Listed—CBC
etanercept (Enbrel®, boDMARD) Listed—CBC Listed—CBC N/A Listed—CBC Listed—CBC N/A N/A N/A
etanercept (Brenzys®, bsDMARD) Under Review Under Review N/A N/A N/A N/A N/A N/A
etanercept (Erelzi®, bsDMARD) Under Review Under Review N/A N/A N/A N/A N/A N/A
golimumab (Simponi®) Listed—CBC Listed—CBC Under Review N/A Listed—CBC N/A N/A N/A
infliximab (Remicade®, boDMARD) Listed—ORC Listed—ORC N/A N/A Listed—ORC N/A N/A N/A
infliximab (Inflectra®, bsDMARD) Listed—CBC Listed—CBC N/A N/A Listed—CBC N/A N/A N/A
rituximab (Rituxan®) Listed—CBC N/A N/A N/A N/A N/A Listed—CBC N/A
sarilumab (Kevzara®) Under Review N/A N/A N/A N/A N/A N/A N/A
secukinumab (Cosentyx®) N/A Under Review N/A N/A Under Review N/A N/A N/A
tocilizumab (Actemra®) Listed—CBC N/A N/A Listed—CBC N/A N/A N/A N/A
ustekinumab (Stelara®) N/A N/A N/A N/A Under Review N/A N/A N/A
apremilast (Otezla®) N/A N/A N/A N/A Under Review N/A N/A N/A
tofacitinib citrate (Xeljanz®) Under Review N/A N/A N/A N/A N/A N/A N/A
11th : Yukon   (Last year: 12th)
generic name (Brand Name) rheumatoid arthritis axial spondyloarthritis juvenile idiopathic arthritis psoriatic arthritis systemic lupus erythematosus vasculitis osteoporosis
ankylosing spondylitis non-radiographic axial spondyloarthritis (not visible on X-ray)
abatacept (Orencia®) Under Review N/A N/A Under Review In Trials N/A N/A N/A
adalimumab (Humira®) Listed—CBC Listed—CBC N/A Under Review Listed—CBC N/A N/A N/A
anakinra (Kineret®) Listed—CBC N/A N/A N/A N/A N/A N/A N/A
belimumab (Benlysta®) N/A N/A N/A N/A N/A Under Review N/A N/A
canakinumab (Ilaris®) N/A N/A N/A Under Review N/A N/A N/A N/A
certolizumab pegol (Cimzia®) Listed—CBC Listed—CBC N/A N/A Listed—CBC N/A N/A N/A
denosumab (Prolia®) N/A N/A N/A N/A N/A N/A N/A Listed—CBC
etanercept (Enbrel®, boDMARD) Listed—ORC Listed—ORC N/A Under Review Listed—CBC N/A N/A N/A
etanercept (Brenzys®, bsDMARD) Listed—CBC Listed—CBC N/A N/A N/A N/A N/A N/A
etanercept (Erelzi®, bsDMARD) Under Review Under Review N/A N/A N/A N/A N/A N/A
golimumab (Simponi®) Listed—CBC Listed—CBC Under Review N/A Listed—CBC N/A N/A N/A
infliximab (Remicade®, boDMARD) Listed—ORC Listed—ORC N/A N/A Listed—ORC N/A N/A N/A
infliximab (Inflectra®, bsDMARD) Listed—CBC Listed—CBC N/A N/A Listed—CBC N/A N/A N/A
rituximab (Rituxan®) Listed—CBC N/A N/A N/A N/A N/A Under Review N/A
sarilumab (Kevzara®) Under Review N/A N/A N/A N/A N/A N/A N/A
secukinumab (Cosentyx®) N/A Under Review N/A N/A Under Review N/A N/A N/A
tocilizumab (Actemra®) Listed—CBC N/A N/A Under Review N/A N/A N/A N/A
ustekinumab (Stelara®) N/A N/A N/A N/A Under Review N/A N/A N/A
apremilast (Otezla®) N/A N/A N/A N/A Under Review N/A N/A N/A
tofacitinib citrate (Xeljanz®) Listed—CBC N/A N/A N/A N/A N/A N/A N/A
12th : NIHB*   (Last year: 11th)
generic name (Brand Name) rheumatoid arthritis axial spondyloarthritis juvenile idiopathic arthritis psoriatic arthritis systemic lupus erythematosus vasculitis osteoporosis
ankylosing spondylitis non-radiographic axial spondyloarthritis (not visible on X-ray)
abatacept (Orencia®) Listed—CBC N/A N/A Listed—CBC In Trials N/A N/A N/A
adalimumab (Humira®) Listed—CBC Listed—CBC N/A Listed—CBC Listed—CBC N/A N/A N/A
anakinra (Kineret®) Declined N/A N/A N/A N/A N/A N/A N/A
belimumab (Benlysta®) N/A N/A N/A N/A N/A Under Review N/A N/A
canakinumab (Ilaris®) N/A N/A N/A Under Review N/A N/A N/A N/A
certolizumab pegol (Cimzia®) Listed—CBC Listed—CBC N/A N/A Listed—CBC N/A N/A N/A
denosumab (Prolia®) N/A N/A N/A N/A N/A N/A N/A Listed—CBC
etanercept (Enbrel®, boDMARD) Listed—CBC Listed—CBC N/A Listed—CBC Listed—CBC N/A N/A N/A
etanercept (Brenzys®, bsDMARD) Under Review Under Review N/A N/A N/A N/A N/A N/A
etanercept (Erelzi®, bsDMARD) Under Review Under Review N/A N/A N/A N/A N/A N/A
golimumab (Simponi®) Listed—CBC Listed—CBC Under Review N/A Listed—CBC N/A N/A N/A
infliximab (Remicade®, boDMARD) Listed—CBC Declined N/A N/A Declined N/A N/A N/A
infliximab (Inflectra®, bsDMARD) Listed—CBC Under Review N/A N/A Under Review N/A N/A N/A
rituximab (Rituxan®) Listed—CBC N/A N/A N/A N/A N/A Under Review N/A
sarilumab (Kevzara®) Under Review N/A N/A N/A N/A N/A N/A N/A
secukinumab (Cosentyx®) N/A Under Review N/A N/A Under Review N/A N/A N/A
tocilizumab (Actemra®) Listed—CBC N/A N/A Listed—CBC N/A N/A N/A N/A
ustekinumab (Stelara®) N/A N/A N/A N/A Under Review N/A N/A N/A
apremilast (Otezla®) N/A N/A N/A N/A Under Review N/A N/A N/A
tofacitinib citrate (Xeljanz®) Listed—CBC N/A N/A N/A N/A N/A N/A N/A

About the report card:
Arthritis Consumer Experts graded each of the provinces by assigning a score based upon number of medications listed, number under review, and number of declined listings. In some cases, information was unavailable from a province or territory's website. This lack of transparency was reflected in grade assignments.

Because provincial formularies change frequently, we encourage you to contact the Ministry of Health in your province with questions you may have about medication listings of concern to you.

Definitions

Declined: The formulary does not reimburse patients prescribed this medication.
In Trials: This medication is undergoing testing for use in treating this disease type.
Listed—CBC: Each province and territory has a process by which medications that are not normally included in the provincial, territorial or federal drug benefit lists are covered (or reimbursed). Approval of this drug is granted on a case-by-case basis.
Listed—ORC: The medication is listed, but the criteria are not supported by medical evidence. Arthritis Consumer Experts considers these overly restrictive criteria (ORC) unacceptable.
N/A: (Not Applicable) No Notice of Compliance (or NOC) has been issued for this medication for this form of arthritis.
Under Review: This drug has been approved by Health Canada for this disease type and the province is considering whether patients should be reimbursed for it.
Unknown: There is no public information available.
CDR: The Common Drug Review (CDR) is part of the Canadian Agency for Drugs and Technologies in Health. The Common Drug Review (CDR) conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Québec). (http://cadth.ca/index.php//cdr)


* Note: The Non-Insured Health Benefits (NHIB) program provides supplementary health benefits, including prescription and non-prescription drugs, for registered First Nations and recognized Inuit throughout Canada.

Disclaimer: The material contained in this or any other ACE publication is provided for general information only. It should not be relied on to suggest a course of treatment for a particular individual or as a substitute for consultation with qualified health professionals who are familiar with your individual medical needs. If you have any healthcare related questions or concerns, you should contact your physician. Never disregard medical advice or delay in seeking it because of something you have read in any ACE publication.